Tag: SGLT2 inhibitors

Medical illustration showing heart protection through genetic-guided therapy with SGLT2 inhibitors
Clinical UpdatesNew StudiesPracticeResearch Digest

Diabetes Drug Dapagliflozin Cuts Heart Failure Risk by 32% in Genetically Vulnerable Patients

New research shows dapagliflozin reduces heart failure risk by 32% in patients with cardiomyopathy-associated genetic variants. The study from Mass…

By
GMJ Practice Desk

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →